116 results about "Premature aging" patented technology

The invention provides an anti-premature senility management method for closely-planted double-layer truncated cone macadamia nut trees, and belongs to the technical field of fruit tree cultivation. The premature senility prevention management method comprises layered nutrition supply and flower and fruit protection management. The layered nutrition supply comprises the following steps: deeply applying a calcium magnesium phosphate fertilizer to the lower layer of soil greater than 60cm, and covering a root controller; organic fertilizers and biological agents are applied to 30-60 cm soil of the middle layer; a macroelement, humic acid and seaweed extract water-soluble fertilizer is applied to the 0-30 cm soil of the upper layer; the flower and fruit protection management comprises the steps that ABA and paclobutrazol are sprayed in the flower bud differentiation period; brassinolide and fluid boron are sprayed in the full-bloom stage; spraying forchlorfenuron and amino acid in a young fruit stage; nAA and monopotassium phosphate are sprayed in the fruit swelling period. Layered nutrition supply and flower and fruit protection management are carried out on the densely-planted double-layer truncated cone macadamia nut trees, premature senility of the densely-planted macadamia nut trees is prevented, branch development of the lower layer is promoted, the tree vigor is balanced, and the high-yield level is maintained.

The invention provides a strain of lactobacillus plantarum YS-AG23 with high antioxidant activity, and a rhizoma polygonati and radix angelicae sinensis fermented product obtained by fermenting rhizoma polygonati and radix angelicae sinensis with the strain of lactobacillus plantarum YS-AG23. In a D-galactose induced premature ovarian failure mouse model, the fermentation product can regulate up the levels of antioxidant and stress protection genes SOD2 and HO-1 and an anti-aging gene SIRT1 by regulating down the expression of a key gene AGER of an inflammation and oxidative stress pathway, so that the oxidative stress and inflammatory response of model mouse ovarian tissues are remarkably reduced; meanwhile, the serum hormone level can be specifically adjusted, the serum estradiol (E2) level can be increased, the follicle stimulating hormone (FSH) and luteinizing hormone (LH) levels can be reduced to be close to the normal range, the expression of anti-mullerian hormone (AMH) and hormone regulatory gene LHR of ovarian reserve markers can be up-regulated, the proliferative activity and estrogen secretion function of follicular granulosa cells can be improved, and the effect of preventing ovarian reserve is achieved. The wet weight of atrophic uterus and ovary of the model mouse is remarkably increased, uterine and ovary atrophy is effectively reversed, and the ovarian reserve function of the D-galactose induced premature ovarian failure model mouse is recovered. Besides, in an H2O2-induced human dermal fibroblast aging model, the yeast can improve the activity of aging cells in a concentration-dependent manner and reduce the level of reactive oxygen species (ROS) in the cells; in addition, by up-regulating the expression of a collagen synthesis key gene COL1A1 and down-regulating the expression of a cell senescence marker gene p16, skin cell senescence caused by oxidative stress can be effectively improved. In conclusion, the polygonatum sibiricum and angelica sinensis leavening can synchronously improve premature ovarian failure and skin cell senescence caused by oxidative stress by accurately regulating and controlling oxidative stress, inflammatory response and tissue function related genes, and has wide application potential.

The invention discloses sturgeon ovary active peptide with ovary aging resistance and a preparation method of the sturgeon ovary active peptide. According to the invention, sturgeon ovary is taken as a raw material, and peptide with the highest ovarian aging resistance activity is selected from different enzymolysis combinations through an in-vitro anti-oxidation test and an ovarian granular cell and caenorhabditis elegans test; three sturgeon ovary active peptide sequences with ovary senescence resistance activity are screened by virtue of bioinformatics technologies such as mass spectrum identification, molecular docking and the like, and the amino acid sequences of the sturgeon ovary active peptide sequences are Phe-Met-Ile (FMI), Phe-Asp-Pro-Phe (FDPF) and Ser-Trp-Pro-Trp-Gln (SWPWQ). The sturgeon ovarian peptide prepared by the method not only has remarkable anti-premature ovarian failure activity and successfully solves the problem of high-valued utilization of sturgeon byproducts, but also can be used as a natural and efficient functional factor, is widely applied to functional products in the related fields of health care products, cosmetics, medicines and the like, and has a wide application prospect. And the method shows extremely wide market application prospects and huge economic values.

The invention discloses a biological age assessment method, which comprises the following steps: acquiring a key protein index of a to-be-assessed person, and inputting an improved biological age assessment model I to obtain the biological age of the to-be-assessed person; the improved biological age assessment model I is constructed and obtained based on an elastic network regression algorithm by taking proteome data and body composition age of an individual as training data. The invention also discloses a construction method of the model, namely a two-step method. According to the method, the user is allowed to calculate the biological age according to the proteome data of the user, personalized monitoring of the muscle aging state is achieved, and the method has great guiding significance in the aspects of identifying individuals with premature aging of muscle functions and formulating personalized precise anti-aging schemes.

The invention provides application of sturgeon swimming bladder collagen peptide in preparation of a medicine for premature ovarian failure, and relates to the technical field of protein peptide. According to the method, the sturgeon swim bladder is subjected to resource utilization, so that the waste of the sturgeon swim bladder can be effectively reduced, the sturgeon resource can be sustainably utilized, the extraction rate of the sturgeon swim bladder collagen is relatively high, and industrial production is facilitated; meanwhile, collagen peptide obtained after enzymolysis treatment is conducted through alkaline protease can achieve the effects of preventing, treating, inhibiting and improving the premature ovarian failure.

The invention discloses application of amniotic mesenchymal stem cells in preparation of a medicine for improving and / or treating premature ovarian failure. The invention finds that the amniotic mesenchymal stem cells can significantly improve the granular cell proliferation ability and hormone secretion ability, and the premature ovarian failure animal model proves that the amniotic mesenchymal stem cells have leading treatment effects in the aspects of restoring the ovarian functions (hormone secretion, ovary volume and follicle number of each level) of POF mice and improving fertility again. And a foundation is laid for optimizing a treatment strategy of premature ovarian failure and promoting clinical application of mesenchymal stem cell treatment.

The invention discloses a preparation method of mesenchymal stem cells for resisting ovarian granular cell aging. The preparation method comprises the following steps: providing umbilical cord blood stem cells; carrying out induced culture on the umbilical cord blood stem cells, collecting a supernatant after the culture is completed, and separating the supernatant to obtain an exosome; providing mesenchymal stem cells, and performing induced culture on the mesenchymal stem cells by adding the exosome, so as to obtain the required mesenchymal stem cells for resisting ovarian granular cell senescence. According to the preparation method of the mesenchymal stem cells for resisting ovarian granular cell senescence, the mesenchymal stem cells induced by the umbilical cord blood stem cell exosome can be prepared, and the mesenchymal stem cells can be used for treating premature ovarian failure in a whole body vein use mode. The umbilical cord mesenchymal stem cells induced by the stem cell exosome can exert a better immune regulation function, regulate the balance of an immune system and reduce immune-related inflammation and injury so as to delay the senescence of ovarian granular cells.

The invention discloses plant lactobacillus La10 and application thereof in regulating estrogen secretion stability and enhancing ovarian function, and belongs to the technical field of microorganisms. The plant lactobacillus La10 provided by the invention can effectively promote the conversion of free isoflavone (daidzein and genistein), so that the absorption and utilization of intestinal tracts are promoted; the composition has the advantages that the ovarian index and sex hormone estradiol E2 secretion level reduction caused by premature ovarian failure of rats can be obviously improved, and meanwhile, the estrogen secretion level and ovarian index up-regulation caused by mouse hysteromyoma can be improved; the irregular menstruation phenomenon of women is improved, so that the estrogen secretion disorder is regulated. The plant lactobacillus La10 disclosed by the invention has a very wide application range in preparation of functional foods and health-care foods for promoting estrogen balance and protecting female health, and is healthy and safe.

The invention provides a capsule containing supramolecular anti-aging factors and used for improving ovarian functions and a preparation method of the capsule. The capsule is prepared from the following components by weight: 0.4 to 0.8 g of ergothioneine, 5 to 8 g of fruit polyphenol, 10 to 20 g of inositol composition, 5 to 8 g of diindolylmethane, 0.01 to 0.02 g of folic acid and 100 to 200 g of auxiliary materials. High-purity ergothioneine is extracted from pleurotus eryngii through microwave and ultrasonic combination, chiral inositol is extracted from tartary buckwheat seeds, the chiral inositol and myo-inositol are maintained to be in a proper proportion, meanwhile, fruit polyphenol and a small amount of folic acid are used in a matched mode, gelatin and other auxiliary materials are used for preparing a capsule form, the capsule is more convenient to take, the symptoms of premature ovarian failure can be relieved, and the effect of preventing and treating premature ovarian failure is achieved. The raw materials for preparing the capsule are environment-friendly, and the preparation process is simple and suitable for large-scale production.

The application discloses application of NCOA7 circular RNA nanoliposome in preparation of a drug for treating premature ovarian failure or ovarian reserve function decline, and belongs to the technical field of biological medicine.The present application proves that nuclear receptor coactivator 7 (NCOA7) can relieve ovarian aging and significantly improve the ovarian function and fertility of DOR patients.The present application finds that NCOA7 circular RNA nanoliposome treatment can significantly improve the NCOA7 protein expression level of DOR female ovarian granulosa cells, improve the aging phenotype and growth rate of the DOR female ovarian granulosa cells, and has no significant influence on the biological characteristics of the ovarian granulosa cells, thereby providing a new scheme for rescuing the ovarian function and improving the fertility of DOR women.

The present invention provides a novel promoter for lipid synthesis in sebaceous gland cells. By using the novel promoter for lipid synthesis in sebaceous gland cells, a skin barrier damage repairing agent and cosmetics with a skin barrier damage repairing function can be prepared, so that cosmetics for repairing skin barrier damage of at least one type selected from skin dryness, premature skin aging, skin aging, skin pruritus, and senile sebaceous deficiency eczema caused by hypofunction of sebaceous glands and / or reduced sebum secretion can be developed.

The application discloses application of a novel peptide UHP in preparation of a medicine for treating and / or preventing delayed aging, and belongs to the technical field of biological medicines.The novel peptide UHP is composed of 37 L-type amino acids including a transmembrane peptide HIV-TAT.It is proved by cell experiments that the novel peptide UHP significantly improves the aging phenotype of a HGPS cell model simulated by overexpression of progerin and a replicative senescent human normal fibroblast cell, reduces the SA-beta-gal positive cell proportion and the expression of SASP factors, and increases the expression levels of cell proliferation markers Ki67, Lamin B1 and Cyclin A2.It is proved by animal experiments that the novel peptide UHP can improve the progeria phenotype, body weight and exercise capacity of a progeria mouse, relieve fibrosis in multiple tissues, improve the skin aging phenotype, and prolong the survival period of the progeria mouse, thereby providing a new medicine selection for clinical treatment of aging-related diseases.

The invention discloses an extract for promoting health and application thereof, and belongs to the technical field of medical and edible dual-purpose and traditional Chinese medicine health care, and the extract is a special extract obtained from beautiful millettia roots. The beautiful millettia root extract exerts new activity for promoting female health through a new mechanism, and the clinical effect is obviously improved. Experimental research proves that the extract promotes self-renewal of female germline stem cells and directional differentiation of the female germline stem cells into oocytes by promoting expression of Notch1, HES1 and HES5 in a Notch signal channel and regulates the female progestational hormone level, and shows the effects of promoting and recovering development of a second sexual character and preventing symptoms of polycystic ovarian syndrome on ovarian development disorder, and has a good application prospect. The radix millettiae speciosae extract is capable of promoting female physical development and maturation, delaying premature ovarian failure, relieving female depression and anxiety states and keeping female health, belongs to a new target and new mechanism, and makes up the mechanism blank of the radix millettiae speciosae extract in the aspect of keeping female health. The application has innovativeness.

This invention relates to the field of anti-aging drug technology, specifically to the application of small molecule compounds in the preparation of anti-aging drugs. These small molecule compounds competitively block the interaction between KDM6A and the vacuolar ATPase V0 domain subunit ATP6V0C by targeting a specific small molecule binding pocket of the histone demethylase KDM6A, thereby inhibiting the demethylation activity of KDM6A on lysine residue 36 of ATP6V0C. These small molecule compounds can effectively downregulate aging-related β-galactosidase activity, improve cell cycle arrest, and reverse the senescent phenotype of nerve cells induced by the environmental pollutant GenX, making them particularly suitable for combating premature aging of nerve cells induced by perfluorinated and polyfluoroalkyl compounds such as GenX. This technical solution can solve the technical problem of the lack of drugs with clearly defined components, a clear mechanism of action, stable efficacy, and the ability to specifically alleviate aging in existing technologies, and has ideal prospects for widespread application.

The invention provides a culture method for obtaining high-quality hemsley rockvine root calluses, belongs to the technical field of tissue culture, and aims to solve the problems of slow growth, high adventitious root occurrence rate, premature aging of the calluses, serious browning, high death rate after subculture and the like in the hemsley rockvine root callus growth process. The culture method comprises the following steps: step 1, pretreatment of explants; step 2, callus induction culture: putting the treated explant into a callus induction culture medium, and putting the callus induction culture medium in an environment with a day-night temperature difference for callus induction culture; and step 3, subculture and enlarged culture of the callus: stripping the callus generated on the stem segment in the step 2, transferring the callus to a subculture multiplication medium, adjusting the light quality ratio of red light to blue light, and carrying out subculture in an environment with gradually changed day temperature to obtain the high-quality hemsley rockvine root callus. In the subculture process, the content of zeatin is increased, the light quality ratio is adjusted, and the high-quality hemsley rockvine root callus can be obtained in a circulation management mode that the daily temperature is gradually changed.

The invention relates to the technical field of anti-aging drugs, in particular to application of a small molecule compound in preparation of anti-aging drugs. The small molecule compound competitively blocks the interaction between the KDM6A and a vacuolar ATP enzyme V0 structural domain subunit ATP6V0C through a specific small molecule binding pocket of targeted histone demethylase KDM6A, and further inhibits the demethylation activity of the KDM6A on 36th lysine of the ATP6V0C. The small molecule compound can effectively down-regulate the activity of senescence-related beta-galactosidase, improve cell cycle arrest and reverse nerve cell senescence phenotypes induced by environmental pollutant GenX, and is especially suitable for resisting nerve cell premature senescence caused by perfluorinated and polyfluoroalkyl compounds such as GenX. According to the technical scheme, the technical problem that drugs which are definite in component, clear in action mechanism, stable in curative effect and capable of pointedly relieving senescence are lacked in the prior art can be solved, and ideal application and popularization prospects are achieved.

The invention belongs to the technical field of functional foods and health foods, and particularly relates to a composition for improving premature ovarian failure and a preparation method thereof. The composition comprises the following components in parts by weight: 5-15 parts of orange osmanthus pollen, 4-12 parts of flaxseed concentrated powder, 2-8 parts of black-bone chicken peptide, 4-20 parts of rehmannia powder, 2-10 parts of cistanche powder and 1-5 parts of lemon concentrated powder. The composition for improving premature ovarian failure prepared by the invention can reduce the content of follicle stimulating hormone (FSH) and luteinizing hormone (LH) in the serum of a premature ovarian failure rat induced by cyclophosphamide and increase the content of estradiol (E2), thereby achieving the effect of improving premature ovarian failure.

The invention discloses a recombinant chimeric collagen (rCOL-FGFR), a high affinity anti-IL-6 monoclonal antibody (mAb-IL6v3) and a composition of the recombinant chimeric collagen (rCOL-FGFR) and the high affinity anti-IL-6 monoclonal antibody (mAb-IL6v3). The rCOL-FGFR is formed by connecting human-derived III type collagen and an FGFR2D3 structural domain through flexible Linker, and has the characteristic of targeting FGFR2 + cells, and the expression quantity of the rCOL-FGFR is increased by 40% compared with that of wild type collagen. The mAb-IL6v3 is optimized through mismatch PCR and a yeast display technology, and the IL-6 binding affinity (KD = 1.8 nM) of the mAb-IL6v3 is remarkably superior to that of a commercial antibody. Experiments show that when the rCOL-FGFR and the mAb-IL6v3 are combined for use, the SA-beta-gal positive rate can be synergistically reduced, the skin collagen density can be increased to 67.9%, and a remarkable anti-aging effect is shown in cell and animal models. The composition disclosed by the invention can be widely applied to the development of anti-aging medicines and functional cosmetics.

Materials and methods for regenerating senescent cells are provided. Aging cells are transduced with viral vectors to express Oct4, Sox2 and Klf4 proteins for partial cell reprogramming and to express dominant negative NF [kappa] BIA proteins to inhibit secretion phenotypes associated with aging. The materials and methods provided may be used to treat signs and symptoms of premature senility syndrome, premature aging, or natural aging, or to regenerate tissue in a subject experiencing premature aging or having an age-related disease.

The present application provides a kind of transcription factor PpeNAC33 for regulating plant growth and development and chlorophyll degradation, nucleotide sequence is as shown in SEQ.ID.NO.2, amino acid sequence is as shown in SEQ.ID.NO.3.The present application also provides the vector based on the above-mentioned transcription factor, engineering strain.Meanwhile, the application of the above-mentioned transcription factor PpeNAC33 in regulating plant growth and development and chlorophyll degradation is provided.The present application finds a NAC transcriptional regulatory factor PpeNAC33 in the transcriptome analysis of seed abortion peach fruit.Studies have shown that the transcription factor is a key transcription factor for regulating plant growth and development and chlorophyll degradation, and its expression can be accurately regulated by space-time and expression amount, which can be used to realize the accurate control of plant growth process and avoid the occurrence of plant fruit premature aging.

This invention discloses a Polygonatum sibiricum vesicle preparation for treating premature ovarian failure, its preparation method, and its application. The preparation method includes: cleaning Polygonatum sibiricum, juicing, filtering to remove residue, and collecting the juice; subjecting the juice to gradient centrifugation to remove residual plant tissue, plant cells, and plant cell debris; then using an extraction reagent for stepwise precipitation, collecting the precipitate, and resuspending it to obtain the final product. The Polygonatum sibiricum vesicle preparation prepared by this invention can be efficiently taken up by ovarian granulosa cells. It effectively treats premature ovarian failure by activating the Nrf2 signaling pathway, upregulating antioxidant enzyme expression, scavenging reactive oxygen species, restoring mitochondrial membrane potential, inhibiting apoptosis, and restoring the expression levels of estrogen, follicle-stimulating hormone, and anti-Müllerian hormone. The preparation method of this invention is standardized, biocompatible, and safe, and has broad clinical application prospects.

The premature ovarian failure is caused by ovarian function decline and is one of important factors affecting physical and psychological health of women. The invention relates to a technology for reversing premature ovarian failure by using embryonic stem cells (ESCs)-derived extracellular vesicles (ESC-EVs). The ESCs in the early development stage have self-renewal capacity and multidirectional differentiation potential, and have great application prospects in degenerative disease treatment and regenerative medicine. The ESC-EVs is formed by wrapping tiny vesicles with a phospholipid bilayer, carries nucleic acid, protein and other components secreted by the embryonic stem cells, and has a regeneration promoting effect similar to that of the embryonic stem cells; the problems of immunological rejection, ethical restriction, safety and the like are avoided, and compared with stem cells, the extracellular vesicles are more stable and easier to store, so that more and more extracellular vesicles are applied to the field of regenerative medicine. The invention relates to a new technology for treating premature ovarian failure by using embryonic stem cell-derived extracellular vesicles, which can improve the ovarian morphology and ovarian microenvironment, increase the number of primary follicles, anterior sinus follicles and sinus follicles, reduce the number of atresia follicles, reduce the expression of oxidative stress and senescence-related proteins, promote the recovery of ovarian functions and estrus cycle, and improve the curative effect of premature ovarian failure. The technical invention expands the application of the embryonic stem cell source exosome in the field of reproduction.

The application relates to the technical field of plant breeding, and discloses a cultivation method of a powdery mildew-resistant plant and application of a mesophyll-specific expression vector, which comprises the following steps: transforming the mesophyll-specific expression vector into the powdery mildew-resistant plant, so that the mesophyll cells in the powdery mildew-resistant plant can specifically express a powdery mildew-resistant gene MLO; and the powdery mildew-resistant plant is obtained by making the powdery mildew-resistant gene MLO in the plant be mutated. According to the application, the mesophyll-specific expression vector is introduced into the powdery mildew-resistant plant (the plant has a premature aging phenomenon) with the function of the powdery mildew-resistant gene MLO being inactivated, so that the mesophyll cells in the plant can specifically express the powdery mildew-resistant gene MLO, and the plant which is resistant to powdery mildew and has no growth defects is obtained. The cultivation method provided by the application can eliminate the premature aging phenotype of the existing powdery mildew-resistant plant with premature aging, successfully decouples the mlo-mediated disease resistance and growth demand, and provides a new perspective for further analyzing the MLO-mediated disease mechanism research.

The present invention provides an mRNA-polypeptide complex and a preparation method and application thereof. The present invention synthesizes the Smad7-mRNA-polypeptide complex for the first time. The mRNA-polypeptide complex has the function of significantly delaying the aging of primary human trabecular meshwork cells, and can be used for the treatment of glaucoma. It also has the potential to be developed into an inhibitor of other aging diseases, such as neurodegenerative diseases, skin aging, premature aging of stem cells, premature aging of immune cells, etc.; the mRNA-polypeptide complex can effectively inhibit the occurrence of fibrosis of primary human trabecular meshwork cells, and in addition to glaucoma, it also has the potential to be developed into an inhibitor of other fibrotic diseases, such as pulmonary fibrosis, liver fibrosis, kidney fibrosis, myocardial fibrosis, etc.; and the preparation process of the mRNA-polypeptide complex is simple, which is conducive to large-scale production; it has high scientific research and technical application value and medical technology application prospect.

The treatment is intended for the skin and its appendages to improve their general condition and / or sensory comfort It can be chosen from a treatment for the signs of chronological or premature aging, a moisturizing treatment, a treatment for dull and / or tired skin, a treatment for sensory discomfort of the skin, a treatment for oily and / or acne-prone skin, and / or a hair treatment. Pycnidione can be provided in the form of an extract of the biomass of an in-vitro culture of a microorganism capable of producing pycnidione as a secondary metabolism

WATER-SOLUBLE EXTRACT FROM A PLANT OF THE PRUNUS SPECIES TO PREVENT THE DELETE EFFECTS OF THE EXPOSOME. The present invention relates to the use of a flower extract from a plant of the Rosaceae family and the Prunus genus, or a composition thereof, to protect the skin from the deleterious effects of the exposome, including disruption of the barrier function, neurogenic inflammation, irritation, and oxidative stress. The invention is thus intended to prevent the clinical signs of premature aging, including the appearance of hyperpigmentation spots responsible for loss of skin tone uniformity and skin hyperreactivity.

The invention provides a transcription factor PpeNAC33 for regulating and controlling plant growth and development and chlorophyll degradation, the nucleotide sequence of the transcription factor PpeNAC33 is as shown in SEQ.ID.NO.2, and the amino acid sequence of the transcription factor PpeNAC33 is as shown in SEQ.ID.NO.3. The invention also provides a vector and an engineering strain based on the transcription factor. Meanwhile, the invention also provides application of the transcription factor PpeNAC33 in regulation and control of plant growth and development and chlorophyll degradation. According to the invention, an NAC type transcriptional regulatory factor PpeNAC33 is found in transcriptomic analysis of seed abortion peach fruits. Researches show that the transcription factor is a key transcription factor for regulating and controlling plant growth and development and chlorophyll degradation, and the expression of the transcription factor can be accurately regulated and controlled in time, space and expression quantity, so that the transcription factor can be used for accurately controlling the plant growth process, and the premature senility phenomenon of plant fruits is avoided.

The invention belongs to the technical field of medicines, and particularly relates to application of a licorice extract in preparation of a medicine for treating premature ovarian failure. On the basis of network pharmacology prediction and animal experiment verification, through experimental exploration, it is clear that diammonium glycyrrhizinate can treat premature ovarian failure by improving ovarian tissue energy metabolism, reducing the oxidative stress level and inhibiting ovarian cell apoptosis, and also can treat premature ovarian failure by improving the ovarian growth and development microenvironment. According to the present invention, the growth and development rate of ovarian granular cells and membrane cells is improved, the sufficient quantity of granular cells and membrane cells are ensured to secrete female progestational hormone, the damaged ovarian tissue is further protected, the new strategy and hope are provided for the treatment of premature ovarian failure, and the pharmaceutical composition is expected to become the safe and effective treatment drug.

The application discloses application of cell endogenous metabolites in preparation of medicines for treating and / or preventing aging. The cell endogenous metabolites are any one or combination of phosphocreatine, hypotaurine and / or phosphoethanolamine. The application finds that phosphocreatine, hypotaurine and phosphoethanolamine can effectively restore cell growth, reduce cell SA-beta-Gal staining intensity, improve cell mitochondrial function and increase ATP yield, restore cell mitochondrial membrane potential, alleviate damage caused by cell oxidative stress and premature aging, and also prolong the life of nematodes and restore exercise capacity in the middle of aging. Meanwhile, the three metabolites have a synergistic effect, and by adjusting the matching concentration of the three metabolites, the same cell protection effect can be achieved by mixed administration. Since the endogenous metabolites are accurate, efficient and safe, the three cell endogenous metabolites provided by the application can be used for preparing anti-aging medicines.

The invention belongs to the cross technical field of regenerative medicine and traditional Chinese medicine, and discloses a composition for treating premature ovarian failure and a preparation method and application thereof. The composition comprises adult stem cells, traditional Chinese medicine active components consisting of astragaloside and salvianolic acid B in a molar ratio of (1: 1)-(4: 1) and a biodegradable slow-release carrier, and double intervention of'cell repair-microenvironment regulation and control 'is realized through a synergistic strategy of'pretreatment of stem cells by traditional Chinese medicines and targeted slow-release delivery'. Experiments prove that the composition can enable the estrus cycle recovery rate of premature ovarian failure model animals to reach 70%-90% and the number of follicles to be increased by 6-8 times, is obviously superior to the existing single therapy, has a clear mechanism (activating a PI3K / Akt pathway and inhibiting a TGF-beta1 / Smad pathway), and has outstanding clinical transformation value.